Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Guangzhou
Clinical trial register · China

Clinical Trials in Guangzhou, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19187 matching records held by the registry are in this view. Synced 08 Nov 2026, 03:17 UTC
19187
Studies in scope
all four open statuses
11790
Recruiting now
open to new participants
2028
Lead sponsors
across recruiting studies
Top sites
Beijing 5576 Shanghai 3879 Guangzhou 3345 Hangzhou 1819 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Sun Yat-sen University444 Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University184 Nanfang Hospital, Southern Medical University138 AstraZeneca136 Guangdong Provincial People's Hospital82
Site location
Beijing5576 Shanghai3879 Guangzhou3345 Hangzhou1819 Wuhan1343
All 625 locations
Target enrolment
to

Trials with a site in Guangzhou

3345 of 19187 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
Sun Yat-sen University
Phase 3
260
Guangzhou, Changsha, Fuzhou, Hangzhou, Nanning
2026-04-16
Recruiting
Xuekui Liu
Phase 2
40
Guangzhou
2026-04-15
Recruiting
Akeso
Phase 3
386
Guangzhou
2026-04-15
Recruiting
Nanfang Hospital, Southern Medical University
Not applicable
174
Guangzhou
2026-04-14
Active, closed
Hangzhou Gensciences Biopharmaceutical Co., Ltd.
Phase 3
60
Tianjin, Fuyang, Fuzhou, Ganzhou, Guangzhou, Hefei, Huai'an, Jinan
2026-04-14
Recruiting
RATS Sleeve Lobectomy After Neo-Chemo-IO for NSCLC
NCT07541521Stage IIB-III NSCLC, Sleeve Lobectomy, Robotic Surgery, Neoadjuvant Chemoimmunotherapy
Shanghai Chest Hospital
Observational
100
Fuzhou, Guangzhou, Shenzhen, Nanjing, Qingdao, Tianjing, Shanghai
2026-04-13
Recruiting
Boehringer Ingelheim
Phase 3
670
Beijing, Bengbu, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin
2026-04-13
Recruiting
BeOne Medicines
Phase 1
84
Beijing, Chongqing, Fuzhou, Guangzhou, Yichang, Shanghai
2026-04-13
Recruiting
Pei-Rong Ding
Phase 2/3
160
Guangzhou
2026-04-10
Recruiting
Sun Yat-sen University
Phase 2
47
Guangzhou
2026-04-10
Recruiting
magAssist, Inc.
Not applicable
204
Beijing, Changsha, Guangzhou, Nanchang, Shanghai, Shenyang, Suzhou, Xi'an
2026-04-09
Recruiting
AMG 436 as Monotherapy and Combination Therapy in Participants With MSI-H/dMMR Solid Tumors
NCT07403721Metastatic or Locally Advanced Solid Tumors With Microsatellite Instability-high (MSI-H) or Mismatched Repair Deficiency (dMMR)
Amgen
Phase 1
464
Guangzhou, Shanghai
2026-04-08
Recruiting
Zhongshan Ophthalmic Center, Sun Yat-sen University
Not applicable
224
Guangzhou
2026-04-08
Recruiting
Zhongshan Ophthalmic Center, Sun Yat-sen University
Not applicable
100
Guangzhou
2026-04-08
Recruiting
Wuhan Humanwell Innovative Drug Research and Development Center Limited Company
Phase 1
56
Guangzhou
2026-04-07
Recruiting
Zhujiang Hospital
Phase 2
92
Guangzhou
2026-04-07
By invitation
Peritoneal Dialysis (PD) Specialized LLM for PD Management
NCT07539428Peritoneal Dialysis (PD), Large Language Models
First Affiliated Hospital, Sun Yat-Sen University
Not applicable
150
Guangzhou
2026-04-05
Recruiting
RemeGen Co., Ltd.
Phase 3
574
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou, Dongguan, Guangzhou
2026-04-03
Active, closed
A Study of CS060380 Tablets in Patients With MASH and Obesity
NCT07466017Metabolic Dysfunction-associated Steatohepatitis (MASH), Obesity
DrugsCS060380·Semaglutide
Cascade Pharmaceuticals, Inc
Phase 2
130
Hefei, Guangzhou, Shijiazhuang, Nanjing, Shanghai, Hangzhou, Ningbo, Wenzhou
2026-04-02
Recruiting
Changhai Hospital
Not applicable
150
Fuzhou, Quanzhou, Guangzhou, Qingyuan, Zhanjiang, Shanghai
2026-04-02
Recruiting
Beijing Tiantan Hospital
Phase 3
1,192
Beijing, Chongqing, Guangzhou, Baoding, Zhangjiakou, Zunhua, Mengzhou, Nanle
2026-04-02
Recruiting
A Study of HDM2020 in Patients With Advanced Sq-NSCLC
NCT07638891Squamous Non-small Cell Lung Cancer(NSCLC)
DrugHDM2020
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Phase 1
150
Guangzhou
2026-04-01
Recruiting
Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer
NCT06768931Breast Cancer, Triple Negative Breast Cancer (TNBC), Early Stage Breast Cancer, Immunotherapy
Sun Yat-sen University
Phase 2
192
Lanzhou, Dongguan, Guangzhou, Zhanjiang, Zigong
2026-04-01
Not yet open
Ischemic Preconditioning Reduces the Severity of Acute Kidney Injury After Partial Nephrectomy
NCT07497958Renal Cell Carcinoma (RCC), Renal Function Abnormal
Sun Yat-sen University
Not applicable
174
Guangzhou
2026-04-01
Recruiting
Sun Yat-sen University
Phase 2
52
Guangzhou
2026-04-01
Recruiting
EMD Serono Research & Development Institute, Inc.
Phase 3
202
Fuzhou, Guangzhou, Shijiazhuang, Luoyang, Baotou, Nanjing, Suzhou, Changchun
2026-04-01
Recruiting
Sun Yat-sen University
Phase 2
37
Guangzhou
2026-04-01
Recruiting
Guangdong Provincial People's Hospital
Not applicable
172
Guangzhou
2026-04-01
Not yet open
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Not applicable
386
Guangzhou
2026-04-01
Recruiting
Effects of Different Tunnel Methods in PICC Catheterization
NCT07594704PICC Line Placement, PICC-associated Thrombosis
Sun Yat-sen University
Not applicable
284
Guangzhou
2026-04-01
Not yet open
Nanfang Hospital, Southern Medical University
Phase 4
100
Dongguan, Guangzhou, Heyuan, Qingyuan, Shaoguan, Haikou, Ganzhou
2026-04-01
Not yet open
Zhujiang Hospital
Observational
200
Guangzhou
2026-04-01
Active, closed
The Hong Kong Polytechnic University
Not applicable
36
Guangzhou
2026-04-01
Not yet open
Impact of Postoperative Radiotherapy Versus PD-1 Inhibitor Maintenance on Survival in Resectable Locally Advanced Oral and Oropharyngeal Squamous Cell Carcinoma
NCT07457099Locally Advanced Oral Squamous Cell Carcinoma, Locally Advanced Oropharyngeal Squamous Cell Carcinoma
Zhujiang Hospital
Observational
85
Guangzhou
2026-04-01
By invitation
HVA in the Treatment of Mixed-Phenotype Acute Leukemia(MPAL).
NCT07517510Newly Diagnosed Mixed Phenotype Acute Leukemia (MPAL)
Guangdong Second Provincial General Hospital
Phase 2
40
Guangzhou
2026-04-01
Recruiting
AstraZeneca
Phase 2
60
Beijing, Changchun, Changsha, Chengdu, Foshan, Fuzhou, Guangzhou, Harbin
2026-04-01
By invitation
VEN+IDAC vs IDAC in AML
NCT07537257AML (Acute Myelogenous Leukemia)
DrugsVentoclax·Cytarabine
Guangdong Second Provincial General Hospital
Phase 2/3
232
Guangzhou
2026-04-01
Recruiting
Nanfang Hospital, Southern Medical University
Phase 2
126
Foshan, Gaozhou, Guangzhou, Huizhou, Zhaoqing, Liuzhou
2026-04-01
Not yet open
The First Affiliated Hospital of Guangzhou Medical University
Phase 2
45
Guangzhou
2026-04-01
Not yet open
Zhujiang Hospital
Observational
200
Guangzhou
2026-04-01
Not yet open
First-In-Human Study of KHN922 for Injection
NCT07514975Advanced Solid Tumors Cancer
Chengdu Kanghong Biotech Co., Ltd.
Phase 1/2
276
Guangzhou
2026-04
Not yet open
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Observational
3,000
Guangzhou, Guankou
2026-04
Not yet open
Nutritional + Usual Corticosteroids Randomized Trial for Immune-Related pneumoniA - Therapeutic Utilization Evaluation
NCT07554885Immune Checkpoint Inhibitor-Related Pneumonitis, Drug-Related Side Effects and Adverse Reactions, Neoplasms
DrugMethylprednisolone
Guangzhou Institute of Respiratory Disease
Not applicable
60
Guangzhou
2026-04
Not yet open
Sun Yat-sen University
Phase 2
76
Guangzhou
2026-04
Not yet open
The First Affiliated Hospital of Guangzhou Medical University
Phase 2
150
Guangzhou
2026-04
Not yet open
Zhonghao Fang
Observational
500
Guangzhou
2026-04
Not yet open
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Phase 2
78
Guangzhou, Hangzhou
2026-04
Not yet open
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Observational
3,000
Guangzhou, Guankou
2026-04
Not yet open
Sun Yat-sen University
Phase 2
30
Guangzhou
2026-03-31
Recruiting
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3
177
Hefei, Beijing, Chongqing, Fuzhou, Lanzhou, Guangzhou, Nanning, Guiyang
2026-03-31
Recruiting
Biocity Biopharmaceutics Co., Ltd.
Phase 1/2
111
Guangzhou
2026-03-31
Recruiting
Eisai Co., Ltd.
Phase 2
256
Bengbu, Beijing, Chongqing, Guangzhou, Shantou, Nanning, Guiyang, Luoyang
2026-03-31
Active, closed
Clinical Characteristics of Recompensation
NCT07651683Cirrhosis, Alcohol Related Liver Disease, HBV (Hepatitis B Virus), Recompensation
Third Affiliated Hospital, Sun Yat-Sen University
Observational
300
Guangzhou
2026-03-31
Recruiting
BioNTech SE
Phase 1/2
533
Chongqing, Guangzhou, Hangzhou, Shanghai, Tianjin
2026-03-30
Not yet open
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Observational
5,000
Guangzhou
2026-03-30
Recruiting
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 3
398
Guangzhou
2026-03-30
Recruiting
Fujian Medical University
Not applicable
1,312
Hefei, Fuzhou, Xiamen, Guangzhou, Harbin, Zhengzhou, Changsha, Dalian
2026-03-29
Recruiting
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Phase 2
288
Guangzhou
2026-03-28
Recruiting
An Open-Label, Phase I Clinical Trial of Super CAR-T With GPC3-Positive Advanced Hepatocellular Carcinoma
NCT07493044Advanced Hepatocellular Carcinoma (HCC), GPC3 Positive Hepatocellular Carcinoma
Guangzhou FineImmune Biotechnology Co., LTD.
Phase 1
15
Guangzhou
2026-03-27
By invitation
Zhenyu Zhang
Not applicable
72
Guangzhou
2026-03-27
Recruiting
Sun Yat-sen University
Phase 2
34
Guangzhou
2026-03-27
Recruiting
Chongqing Claruvis Pharmaceutical Co., Ltd.
Phase 3
300
Beijing, Chengdu, Guangdong, Guangzhou, Hefei, Huai'an, Kaifeng, Kunming
2026-03-27
Recruiting
LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis
NCT07415044Ulcerative Colitis (UC), Ulcerative Colitis, Active Moderate, Ulcerative Colitis, Active Severe
DrugZotemtegrast
Eli Lilly and Company
Phase 2
1,431
Binzhou, Changzhou, Chengdu, Chongqing, Foshan, Guangzhou, Harbin, Hefei
2026-03-26
Recruiting
Bristol-Myers Squibb
Phase 1/2
474
Beijing, Guangzhou, Tianjin, Harbin, Changsha Shi, Nanjing, Shanghai Shi
2026-03-26
Not yet open
chenxu
Phase 2
146
Guangzhou
2026-03-26
Recruiting
Hangzhou Sumgen Biotech Co., Ltd.
Phase 2
120
Beijing, Chongqing, Xiamen, Lanzhou, Guangzhou, Shenzhen, Guilin, Nanning
2026-03-26
Recruiting
Eisai Inc.
Phase 2
64
Beijing, Changchun, Guangdong, Guangzhou, Jinan, Nanchang, Shanghai, Zhengzhou
2026-03-26
Recruiting
Beijing Continent Pharmaceutical Co, Ltd.
Phase 2/3
298
Hefei, Beijing, Fuzhou, Lanzhou, Foshan, Guangzhou, Maoming, Shenzhen
2026-03-26
Recruiting
Yuhan Corporation
Phase 2
150
Guangzhou, Shenzhen
2026-03-26
Recruiting
Novartis Pharmaceuticals
Phase 3
770
Fuzhou, Guangzhou, Wuhan, Changsha, Chengdu, Hangzhou, Beijing, Shanghai
2026-03-24
Recruiting
Guangdong Provincial People's Hospital
Not applicable
200
Guangzhou
2026-03-24
Active, closed
Nanfang Hospital, Southern Medical University
Not applicable
440
Guangzhou
2026-03-24
Recruiting
Boehringer Ingelheim
Phase 2
132
Beijing, Chengdu, Guangzhou, Nanchang, Nanjing, Nanning, Shanghai, Sichuan
2026-03-23
Active, closed
Zhongshan Ophthalmic Center, Sun Yat-sen University
Not applicable
316
Guangzhou
2026-03-23
Recruiting
Sun Yat-sen University
Phase 2
40
Guangzhou
2026-03-23
Not yet open
Dermavon Holdings Limited
Phase 2
160
Beijing, Fuzhou, Guangzhou, Shenzhen, Haikou, Shijiazhuang, Tangshan, Zhengzhou
2026-03-20
Recruiting
Clinical Trial of Neoadjuvant mFOLFOX Plus Alvenor for LARC Patients With High YWHAB Expression
NCT07176182Rectal Cancer Patients, Rectal Cancer Stage II, Rectal Cancer Stage III
DrugsMFOLFOX·Adrucil·Oxaliplatin
Sixth Affiliated Hospital, Sun Yat-sen University
Phase 2
236
Guangzhou
2026-03-20
Recruiting
Guangdong Provincial People's Hospital
Phase 2
32
Guangzhou
2026-03-20
Recruiting
Radiotherapy After Prostatectomy for Node Positive Prostate Cancer
NCT07477626Prostate Cancer (Post Prostatectomy), Radiotherapy; Image-Guided, Prostate Cancer Non-Metastatic, Androgen Deprivation Therapy
Sun Yat-sen University
Phase 3
372
Dongguan, Guangzhou, Zhanjiang, Zhengzhou, Chengdu, Hangzhou, Beijing, Shanghai
2026-03-20
Recruiting
Sun Yat-sen University
Phase 2
105
Guangzhou
2026-03-20
Recruiting
Bevacizumab Plus FSRT Versus Hippocampus-Avoidant WBRT in Lung Adenocarcinoma With Extensive Brain Metastases
NCT07481786Lung Adenocarcinoma, Brain Metastases, Radiotherapy, Intensity-Modulated, Bevacizumab
DrugBevacizumab
Sun Yat-sen University
Phase 3
220
Chongqing, Guangzhou
2026-03-20
Recruiting
Jiangsu HengRui Medicine Co., Ltd.
Phase 1/2
282
Guangzhou, Shenyang
2026-03-19
Active, closed
AstraZeneca
Observational
146
Guangzhou, Shenyang, Jinan, Changchun, Changsha, Chengdu, Haikou, Kunming
2026-03-19
Recruiting
Early Complications After Flow Diverter Versus Stent-Assisted Coiling for Unruptured Wide-Neck Intracranial Bifurcation Aneurysms
NCT07754188Unruptured Intracranial Aneurysm, Intracranial Bifurcation Aneurysm, Wide-Neck Aneurysm
Nanfang Hospital, Southern Medical University
Observational
274
Guangzhou
2026-03-19
Recruiting
Beijing Tide Pharmaceutical Co., Ltd
Phase 2
200
Guangzhou
2026-03-18
Recruiting
The Third Affiliated Hospital of Southern Medical University
Not applicable
276
Guangzhou
2026-03-18
Recruiting
A Phase II Trial of G01 Eye Drops for Glaucomatous Optic Neuropathy
NCT07777861Primary Open-Angle Glaucoma, Optic Nerve Injury
Qingdao WanMing BioCell Pharmaceutics Co.,Ltd.
Phase 2
90
Beijing, Guangzhou, Shantou, Changsha, Tianjin, Hangzhou, Wenzhou
2026-03-18
Recruiting
Merck Sharp & Dohme LLC
Phase 3
400
Beijing, Chongqing, Fuzhou, Guangzhou, Nanning, Hshijiazhuang, Wuhan, Changsha
2026-03-18
Recruiting
SBRT Versus Surgical Resection for Small HCC
NCT07381660Hepatocellular Carcinoma (HCC)
Sun Yat-sen University
Phase 3
390
Guangzhou
2026-03-18
Recruiting
PregnAncy-Related Aortic DISsEction in China
NCT07672210Pregnancy Complication, Aortic Dissection, Marfan Syndrome, Loeys-Dietz Syndrome
DeltaHealth Hospital · Shanghai
Observational
500
Shanghai, Beijing, Guangzhou, Wuhan
2026-03-17
Recruiting
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Phase 3
364
Guangzhou
2026-03-17
Recruiting
TransThera Sciences (Nanjing), Inc.
Phase 2
94
Guangzhou, Wuhan, Changsha, Nanjing, Jinan, Linyi, Hangzhou, Beijing
2026-03-17
Recruiting
United Innomed(Shanghai) Limited
Not applicable
330
Fuzhou, Lanzhou, Guangzhou, Guiyang, Zhengzhou, Changsha, Nanchang, Shanghai
2026-03-16
Recruiting
Bristol-Myers Squibb
Phase 1/2
198
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Nanning, Harbin, Nanyang
2026-03-16
Recruiting
Sun Yat-sen University
Phase 2
50
Guangzhou
2026-03-15
Recruiting
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 1
15
Guangzhou
2026-03-15
Active, closed
Guangdong Provincial People's Hospital
Phase 4
166
Guangzhou
2026-03-13
Recruiting
Bristol-Myers Squibb
Phase 2/3
690
Beijing, Fuzhou, Guangzhou, Nanning, Harbin, Weihui, Zhengzhou, Wuhan
2026-03-13
Recruiting
Sanofi
Phase 2/3
526
Beijing, Chengdu, Guangzhou, Hangzhou, Jinan, Nanchang, Nanning, Shanghai
2026-03-13
Recruiting
Effect of EIT-guided PEEP in ARDS Patients
NCT06990477ARDS (Acute Respiratory Distress Syndrome)
Southeast University, China
Not applicable
2,400
Hefei, Shanghai, Guangzhou, Zhengzhou, Hangzhou, Nanjing, Xuzhou, Nanchang
2026-03-13
Recruiting
Bristol-Myers Squibb
Phase 3
750
Beijing, Fuzhou, Xiamen, Zhangzhou, Guangzhou, Shantou, Nanning, Harbin
2026-03-12
Recruiting
Sun Yat-sen University
Phase 2
243
Dongguan, Guangzhou, Shenzhen, Zhanjiang
2026-03-12
Recruiting
Takeda
Phase 3
1,182
Bengbu, Beijing, Guangzhou, Wuhan, Zhuzhou, Baotou Shi, Pingxiang, Linyi Shi
2026-03-11
Recruiting
Avistone Biotechnology Co., Ltd.
Phase 2
40
Guangzhou
2026-03-11
Recruiting
Reistone Biopharma Company Limited
Phase 2
300
Guangzhou
2026-03-10
Recruiting
A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease
NCT07332481Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus (CLE)
DrugEnpatoran
EMD Serono Research & Development Institute, Inc.
Phase 3
202
Guangzhou, Ganzhou
2026-03-10
Recruiting
Guangdong Provincial People's Hospital
Observational
2,000
Guangzhou
2026-03-10
Not yet open
Sun Yat-sen University
Not applicable
200
Guangzhou
2026-03-10
Recruiting
Novartis Pharmaceuticals
Phase 2
210
Guangzhou, Wuhan, Beijing, Shanghai
2026-03-09
Recruiting
Eli Lilly and Company
Phase 4
150
Beijing, Changsha, Guangdong, Guangzhou, Lanzhou, Nanchang, Shanghai, Taizhou
2026-03-09
Recruiting
FindCure Biosciences (ZhongShan) Co., Ltd.
Early Phase 1
10
Guangzhou
2026-03-09
Recruiting
Guangdong Hengrui Pharmaceutical Co., Ltd
Phase 2
84
Guangzhou, Shanghai
2026-03-09
Recruiting
Effectiveness of tTIs for Improving Consciousness in Patients With DoC
NCT07539740Disorders of Consciousness, Vegetative State, Minimally Conscious State
Zhujiang Hospital
Not applicable
136
Guangzhou
2026-03-08
Recruiting
Celecoxib Plus R-CHOP vs R-CHOP in Newly Diagnosed Advanced CD5+ DLBCL
NCT07494565Diffuse Large B-Cell Lymphoma (DLBCL), CD5 Positive
DrugsR-Chop·Celecoxib
Sun Yat-sen University
Phase 2
60
Guangzhou
2026-03-06
Recruiting
AstraZeneca
Observational
2,100
Beijing, Changsha, Chengdu, Guangzhou, Haerbin, Jinan, Nantong, Shanghai
2026-03-06
Recruiting
Phase II Study of RC1416 Injection in COPD
NCT07402551Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
DrugRC1416
Nanjing RegeneCore Biotech Co., Ltd.
Phase 2
180
Hefei, Suzhou, Chongqing, Xiamen, Guangzhou, Huizhou, Jiangmen, Qingyuan
2026-03-06
Recruiting
Janssen Research & Development, LLC
Phase 3
600
Beijing, Changsha, Cheng Du Shi, Dongguan, Guangzhou, Hangzhou, Hefei, Jinhua
2026-03-05
Recruiting
Takeda
Observational
12
Guangzhou, Shanghai, Hangzhou
2026-03-05
Not yet open
The Affiliated Hospital of Qingdao University
Not applicable
18
Guangzhou, Qingdao, Tai’an, Chongqing
2026-03-05
Recruiting
Sun Yat-sen University
Phase 2
80
Guangzhou
2026-03-05
Recruiting
ART Trial: Transcatheter J-VALVE Versus Surgery for Aortic Regurgitation Therapy
NCT07453407Aortic Regurgitation, Aortic Valve Insufficiency, Aortic Insufficiency
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
1,250
Hefei, Beijing, Fuzhou, Guangzhou, Zhengzhou, Hong Kong, Wuhan, Changsha
2026-03-05
Recruiting
Incyte Corporation
Phase 3
700
Beijing, Changsha, Chengdu, Chongqing, Foshan, Fuzhou, Guangzhou, Hangzhou
2026-03-05
Not yet open
Dermavon Holdings Limited
Phase 2/3
540
Bengbu, Wuhu, Guangzhou, Chengde, Handan, Shijiazhuang, Harbin, Nanyang
2026-03-03
Recruiting
Janssen Research & Development, LLC
Phase 1/2
60
Guangzhou, Harbin, Shanghai
2026-03-03
Recruiting
Shanghai Ark Biopharmaceutical Co., Ltd.
Phase 2/3
290
Beijing, Guangzhou, Cangzhou, Nanyang, Zhengzhou, Wuhan, Hangzhou, Rui’an
2026-03-03
Recruiting
Bambusa Therapeutics
Phase 1/2
64
Beijing, Guangzhou, Changsha, Nanjing, Jinan, Qingdao, Yantai, Zibo
2026-03-02
Recruiting
Downstaging and RATS After Neo-Chemo-IO: Impact on Surgical Outcomes in NSCLC
NCT07528066Neoadjuvant Chemoimmunotherapy, Robotic Pulmonary Resection, Stage IIB-III NSCLC
Shanghai Chest Hospital
Observational
200
Fuzhou, Guangzhou, Shenzhen, Nanjing, Qingdao, Tianjing, Shanghai
2026-03-02
Not yet open
Guangdong Provincial People's Hospital
Phase 2
30
Guangzhou
2026-03-01
Recruiting
Sixth Affiliated Hospital, Sun Yat-sen University
Phase 4
312
Guangzhou
2026-03-01
Not yet open
AI Models in Clinical Pathology Diagnosis: A Multicenter RCT
NCT07408167Pathology Foundation Model
Nanfang Hospital, Southern Medical University
Not applicable
2,060
Chongqing, Guangzhou, Zhengzhou
2026-03-01
Recruiting
West China Hospital
Observational
2,000
Hefei, Chongqing, Guangzhou, Harbin, Wuhan, Nanjing, Tianjin
2026-03-01
Recruiting
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Observational
396
Guangzhou
2026-03-01
Recruiting
First Affiliated Hospital of Zhejiang University
Phase 3
186
Fuzhou, Guangzhou, Zhengzhou, Wuhan, Changsha, Nanjing, Jinan, Hangzhou
2026-03-01
Recruiting
Pulsatile High-dose Furmonertinib in EGFR-mutant NSCLC With Leptomeningeal Metastasis
NCT07348965NSCLC (Advanced Non-small Cell Lung Cancer), Leptomeningeal Metastasis, Furmonertinib, EGFR Activating Mutation
Guangzhou University of Traditional Chinese Medicine
Not applicable
42
Guangzhou
2026-03-01
Not yet open
A Phase I Study of FZ-AD005 in Patients With High-Grade Glioma (HGG)
NCT07455045High Grade Glioma (III or IV), Diffuse Midline Glioma (DMG), Glioblastoma (GBM)
DrugFZ-AD005
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
Phase 1
40
Guangzhou
2026-03-01
Recruiting
Clinical Eficacy of Extracorporeal Shock Wave Therapy on Patellar Tendinitis
NCT07401758Shock Wave Threapy for Patellar Tendinitis
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Not applicable
38
Guangzhou
2026-03-01
Not yet open
ArcFlex Sheath in TAVR Trial
NCT07320274Valve Disease, Aortic
Sun Yat-sen University
Not applicable
180
Guangzhou
2026-03-01
Not yet open
Non-intubated Versus Intubated Anesthesia for Thoracoscopic Sublobar Resection
NCT07395375Pulmonary Nodules, Lung Neoplasms, Thoracic Surgery
The First Affiliated Hospital of Guangzhou Medical University
Not applicable
1,600
Guangzhou
2026-03-01
Not yet open
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 3
142
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou, Guangzhou, Meizhou
2026-03
Not yet open
Shanghai Henlius Biotech
Phase 2/3
720
Guangzhou
2026-03
Recruiting
Theory-Based Parenting Intervention for Preschool Children's Health Behaviors
NCT07458009Preschool Children's Health Behaviors, Parental Support
Sun Yat-sen University
Not applicable
80
Guangzhou
2026-02-28
Not yet open
Akeso
Phase 2
160
Guangzhou, Shanghai
2026-02-28
Not yet open
The Affiliated Hospital of Qingdao University
Phase 1/2
9
Guangzhou, Qingdao, Tai’an, Chongqing
2026-02-28
Not yet open
Safety And Recovery Of Tubeless Strategy In Uniportal VATS Wedge Resection
NCT07395349Pulmonary Nodule, Pneumothorax, Postoperative Complications
The First Affiliated Hospital of Guangzhou Medical University
Not applicable
300
Guangzhou
2026-02-28
Recruiting
InxMed (Shanghai) Co., Ltd.
Phase 1/2
92
Beijing, Fuzhou, Guangzhou, Zhengzhou, Luoyang, Changsha, Nanjing, Shengyang
2026-02-28
Not yet open
Sun Yat-sen University
Phase 1/2
122
Guangzhou
2026-02-28
Not yet open
The First Affiliated Hospital of Guangzhou Medical University
Not applicable
30
Guangzhou
2026-02-28
Recruiting
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1/2
465
Beijing, Chongqing, Guangzhou, Guanzhou, Zhongshan, Nanning, Cangzhou, Harbin
2026-02-26
Recruiting
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1
66
Guangzhou, Zhengzhou, Chengdu, Luzhou, Hangzhou
2026-02-26
Recruiting
Suzhou BlueHorse Therapeutics Co., Ltd.
Phase 2
45
Guangzhou, Zhengzhou, Chengdu
2026-02-26
Not yet open
Zhongshan Ophthalmic Center, Sun Yat-sen University
Not applicable
128
Guangzhou
2026-02-24
Not yet open
Sun Yat-sen University
Phase 3
184
Guangzhou
2026-02-24
Recruiting
Xiangya Hospital of Central South University
Phase 4
152
Guangzhou, Changsha
2026-02-24
Recruiting
Guangzhou Concord Cancer Center
Not applicable
65
Guangzhou
2026-02-24
Recruiting
AstraZeneca
Phase 3
508
Beijing, Changchun, Changsha, Chongqing, Guangzhou, Hefei, Nanchang, Nanjing
2026-02-23
Not yet open
Pedicled Lateral Chest Wall Lymph-Adipofascial Flap to Prevent Arm Lymphedema After Breast Cancer Surgery
NCT07415200Breast Cancer-Related Lymphedema, Breast Cancer, Postoperative Complications
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Not applicable
100
Guangzhou
2026-02-20
Recruiting
Astellas Pharma Global Development, Inc.
Phase 3
614
Guangzhou, Shanghai
2026-02-17
Recruiting
Boehringer Ingelheim
Phase 3
286
Baotou, Beijing, Changchun, Changsha, Chengdu, Guangzhou, Hangzhou, Lanzhou
2026-02-16
Recruiting
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 2/3
344
Bengbu, Wuhu, Beijing, Chongqing, Fuzhou, Guangzhou, Shijiazhuang, Luoyang
2026-02-13
Recruiting
Gelaspan vs Crystalloid Therapy in Sepsis
NCT07172451Sepsis, Intra-Abdominal Infections
Shanghai Zhongshan Hospital
Phase 4
318
Guangzhou, Nanjing, Suzhou, Xuzhou, Shanghai, Chengdu, Tianjing, Hangzhou
2026-02-13
Recruiting
Pfizer
Phase 2/3
1,156
Chizhou, Fuyang, Hefei, Beijing, Chongqing, Guangzhou, Huizhou, Xinxiang
2026-02-11
Recruiting
Sun Yat-sen University
Phase 2
59
Guangzhou
2026-02-10
Recruiting
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 3
446
Zhanjiang, Guangzhou, Shantou
2026-02-10
Recruiting
Sun Yat-sen University
Phase 2
142
Guangzhou
2026-02-10
Recruiting
Eli Lilly and Company
Phase 3
800
Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hefei, Kunming
2026-02-10
Recruiting
Nanfang Hospital, Southern Medical University
Not applicable
266
Guangzhou
2026-02-10
Recruiting
Eli Lilly and Company
Phase 3
900
Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Guiyang, Hefei, Huzhou
2026-02-10
Recruiting
Eli Lilly and Company
Phase 3
1,000
Beijing, Changsha, Chaohu, Chengdu, Guangzhou, Haidian District, Hefei, Huzhou
2026-02-09
Active, closed
Janssen Research & Development, LLC
Phase 2
168
Beijing, Chaoyang District, Guangzhou, Shanghai
2026-02-08
Recruiting
Eli Lilly and Company
Phase 3
1,980
Beijing, Chengdu, Guangzhou, Hefei, Jinan, Luoyang Shi, Nanchang, Nanjing
2026-02-06
Recruiting
Shanghai Henlius Biotech
Phase 2
120
Hefei, Fu'zhou, Guangzhou, Nanning, Cangzhou, Harbin, Xinxiang, Wuha
2026-02-05
Recruiting
Hebei Senlang Biotechnology Inc., Ltd.
Early Phase 1
12
Guangzhou
2026-02-04
Recruiting
Janssen Research & Development, LLC
Phase 3
400
Beijing, Chengdu, Guangzhou, Hangzhou, Nanjing, Nanning, Shanghai, Wenzhou
2026-02-04
Recruiting
AstraZeneca
Phase 3
2,130
Beijing, Changde, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin
2026-02-03
Recruiting
Sun Yat-sen University
Phase 2
94
Guangzhou
2026-02-03
Recruiting
Li Li
Observational
716
Guangzhou
2026-02-02
Recruiting
Peiyi Xie
Observational
300
Guangzhou, Maoming
2026-02-01
Not yet open
Cerebral Arteriovenous Malformation With Aneurysm: Epidemiology, Clinical Features, and Prognosis
NCT07353736Cerebral Arteriovenous Malformation, Intracranial Arterial Diseases, Intra Cerebral Hemorrhage, Intracranial Aneurysm
Duan Chuanzhi
Observational
630
Guangzhou
2026-02-01
By invitation
Sun Yat-sen University
Observational
138
Guangzhou
2026-02-01
Not yet open
Zheng Min
Phase 2
25
Guangzhou
2026-02-01
Not yet open
Tubeless Strategy for Enhanced Recovery After Sublobar Resection
NCT07409129Pulmonary Nodules, Early Stage Lung Cancer (I and II), Thoracoscopic Surgery, Sublobar Resection
The First Affiliated Hospital of Guangzhou Medical University
Not applicable
138
Guangzhou
2026-02-01
Active, closed
Jinan University Guangzhou
Not applicable
300
Guangzhou
2026-02-01
Not yet open
Sun Yat-sen University
Early Phase 1
25
Guangzhou
2026-02-01
Not yet open
Sun Yat-sen University
Phase 2
36
Guangzhou
2026-02-01
Not yet open
Guangzhou Medical University
Not applicable
40
Guangzhou
2026-02-01
Not yet open
Lei Huang
Not applicable
66
Guangzhou
2026-02
Not yet open
Golidocitinib for Refractory Immune-related Hematologic Toxicities of Advanced Lung Cancer
NCT07303881IrAE, Hematologic Disorder, Lung Cancer (Locally Advanced or Metastatic)
DrugGolidocitinib
The First Affiliated Hospital of Guangzhou Medical University
Phase 2
16
Guangzhou
2026-02
Not yet open
Sun Yat-sen University
Phase 2
37
Guangzhou
2026-02
Not yet open
Evopoint Biosciences Inc.
Phase 1/2
150
Guangzhou
2026-01-31
Recruiting
Zorifertinib With Osimertinib for NSCLC With Meningeal Progression
NCT07361705Patients With Advanced Non-small Cell Lung Cancer With Meningeal Progression After Osimertinib Treatment
DrugOsimertinib
Alpha Biopharma (Jiangsu) Co., Ltd.
Phase 1
42
Beijing, Shengyang, Guangzhou, Henan, Shanxi
2026-01-31
Not yet open
Shanghai Henlius Biotech
Phase 1/2
126
Guangzhou
2026-01-31
Recruiting
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 2
80
Guangzhou
2026-01-30
Recruiting
Merck Sharp & Dohme LLC
Phase 1/2
170
Beijing, Fuzhou, Guangzhou, Jiangmen, Harbin, Nanchang, Shanghai, Chengdu
2026-01-29
Recruiting
Fulzerasib Sequential Sintilimab Plus Platinum-Doublet Neoadjuvant Therapy for Resectable KRAS G12C-Mutant NSCLC
NCT07492342Resectable NSCLC, KRAS G12C Mutation, Stage IB-IIIA NSCLC, Neoadjuvant Therapy
DrugsFulzerasib·Sintilimab
Jianxing He
Phase 2
30
Beijing, Guangzhou, Zhejiang
2026-01-29
Recruiting
Nanjing Legend Biotech Co.
Phase 1
38
Bengbu, Guangzhou, Changsha, Xuzhou, Nanchang
2026-01-29
Recruiting
AstraZeneca
Phase 3
400
Beijing, Binzhou, Changsha, Chengdu, Chongqing, Deyang, Fuzhou, Guangzhou
2026-01-28
Recruiting
Johnson & Johnson Medical (Shanghai) Ltd.
Observational
200
Chenzhou, Guangzhou, Nanjing, Nanyang, Taiyuan, Wuhu, Zhengzhou
2026-01-28
Recruiting
Fujian Cancer Hospital
Phase 2
89
Fuzhou, Zhangzhou, Guangzhou, Nanning, Hohhot, Dalian, Jinan, Jining
2026-01-28
Recruiting
Nanjing Leads Biolabs Co.,Ltd
Phase 1/2
220
Guangzhou, Harbin, Zhengzhou, Nanjing, Changchun, Shenyang
2026-01-27
Active, closed
Takeda
Phase 2
91
Beijing, Guangzhou, Wuhan, Shanghai, Hangzhou
2026-01-26
Active, closed
Pacagen, Inc.
Not applicable
190
Guangzhou
2026-01-26
Active, closed
Zhujiang Hospital
Observational
20
Guangzhou
2026-01-26
Active, closed
Sun Yat-sen University
Phase 2
90
Guangzhou
2026-01-23
Recruiting
Efficacy and Safety of Anrikefon for Postoperative Analgesia in Ophthalmic Surgery
NCT07269106Ophthalmic Surgery, Postoperative Pain Management, Opioid Analgesia
DrugsAnrikefon·Nalbuphine
Zhongshan Ophthalmic Center, Sun Yat-sen University
Phase 4
204
Guangzhou, Kunming, Shanghai
2026-01-22
Recruiting
BeOne Medicines
Phase 3
500
Beijing, Chongqing, Fuzhou, Guangzhou, Nanning, Guiyang, Harbin, Zhengzhou
2026-01-22
Recruiting
Sanofi
Phase 3
751
Guangzhou, Huizhou, Shanghai, Wuxi
2026-01-22
Recruiting
Efficacy and Safety of Ivonescimab Monotherapy as First-Line Treatment for PD-L1-Positive, Driver Gene-Negative, Locally Advanced or Metastatic NSCLC: A Multicenter, Prospective, Real-World Cohort Study
NCT07696832Patients Must Have Histologically or Cytologically Confirmed Locally Advanced or Metastatic NSCLC, EGFR Mutation-negative and ALK Rearrangement-negative, Eastern Cooperative Oncology Group Performance Status (ECOG PS) Score of 0 to 2, No Prior Systemic Therapy Received for the Advanced or Metastatic Disease
DrugIvonescimab
Guangdong Association of Clinical Trials
Observational
265
Guangzhou
2026-01-20
Not yet open
The First Affiliated Hospital of Guangzhou Medical University
Phase 1
10
Guangzhou
2026-01-20
Recruiting
Xiamen Amoytop Biotech Co., Ltd.
Phase 3
141
Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Haikou
2026-01-20
Active, closed
Janssen Research & Development, LLC
Phase 2
189
Beijing, Changsha, Chengde, Chengdu, Guangzhou, Sanmenxia, Wuxi, Xi'an
2026-01-20
Recruiting
A Phase II Study of SKB571 in Patients With Lung Cancer
NCT07230405Lung Cancer (Non-Small Cell)
DrugSKB571
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 2
295
Guangzhou, Zhengzhou
2026-01-19
Recruiting
Sixth Affiliated Hospital, Sun Yat-sen University
Not applicable
500
Guangzhou
2026-01-16
Recruiting
Boehringer Ingelheim
Phase 3
400
Beijing, Changchun, Changsha, Chengdu, Guangzhou, Hangzhou, Harbin, Jinan
2026-01-16
Recruiting
Sanofi
Phase 3
751
Guangzhou, Huizhou, Wuxi, Chengdu, Beijing, Hefei, Kunming, Shanghai
2026-01-16
Active, closed
Beijing QL Biopharmaceutical Co.,Ltd
Phase 3
755
Xuancheng, Beijing, Chongqing, Lanzhou, Guangzhou, Huizhou, Nanning, Handan
2026-01-16
Recruiting
Mapping of the Developmental Atlas of the Visual System and Research on Embryonic Neurogenesis Phenomena
NCT07688538Embryonic Development, Retinal Anomalies, Neural Development
Sheng Liu
Observational
200
Guangzhou
2026-01-16
Recruiting
Electro-Acupuncture in Lung cancER : EALER Study
NCT07337096Non Small Cell Lung Cancer, Accupuncture, PD-1 Inhibitors
Guangzhou University of Traditional Chinese Medicine
Not applicable
424
Guangzhou, Nanjing
2026-01-15
Not yet open
Li Zhiming
Phase 2
40
Guangzhou
2026-01-15
Recruiting
Bristol-Myers Squibb
Observational
500
Beijing, Guangzhou, Jiazhuang, Zhengzhou, Suzhou, Changchun, Dalian, Xi'an
2026-01-15
Recruiting
Sintilimab Plus Bevacizumab Biosimilar as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma
NCT07324824Hepatocellular Carcinoma, Neoadjuvant Therapy, Sintilimab, Bevacizimab
DrugsBevacizumab biosimilar·Sintilimab
Sun Yat-sen University
Phase 2
37
Guangzhou
2026-01-14
Recruiting
Sanofi
Phase 3
160
Beijing, Chengdu, Dongguan, Guangzhou, Jiazhuang, Shenyang
2026-01-14
Active, closed
Viatris Pharmaceuticals Co., Ltd.
Phase 2
15
Guangzhou, Shijiazhuang, Luoyang, Zhengzhou, Jiujiang, Nanchang, Beijing
2026-01-14
Recruiting
Innostellar Biotherapeutics Co.,Ltd
Phase 3
388
Hefei, Beijing, Chongqing, Guangzhou, Shantou, Zhongshan, Xingtai, Harbin
2026-01-14
Recruiting
Novartis Pharmaceuticals
Phase 1/2
181
Guangzhou
2026-01-13
By invitation
Xiangya Hospital of Central South University
Observational
1,500
Beijing, Guangzhou, Jinan, Shanghai
2026-01-13
Recruiting
Qunxing Li,MD
Not applicable
60
Guangzhou
2026-01-12
Recruiting
Vibrant Sciences Limited
Phase 1/2
146
Guangzhou
2026-01-12
Recruiting
LDRT Combined With Toripalimab and Chemotherapy for Recurrent/Metastatic NPC
NCT07325539Nasopharyngeal Cancinoma (NPC), Nasopharangeal Cancer
DrugsToripalimab·Gemcitabine·Cisplatin
Sun Yat-sen University
Phase 2
55
Guangzhou, Shenzhen
2026-01-12
Recruiting
Diagnostic Biomarkers for Checkpoint Inhibitor-related Pneumonitis
NCT07340892Checkpoint Inhibitor-related Pneumonitis
Zhou Chengzhi
Observational
60
Guangzhou
2026-01-10
Active, closed
A Study of SHR-1819 in Patients With Moderate-to-severe Atopic Dermatitis
NCT07321951Moderate-to-severe Atopic Dermatitis
DrugSHR-1819
Guangdong Hengrui Pharmaceutical Co., Ltd
Phase 2
201
Guangzhou, Hangzhou
2026-01-09
Recruiting
Shanghai SciBrunch Therapeutics Co., Ltd.
Phase 1/2
210
Hefei, Beijing, Guangzhou, Harbin, Zhengzhou, Wuhan, Xuzhou, Shenyang
2026-01-08
Recruiting
Suzhou Forlong Biotechnology Co., Ltd
Phase 1/2
130
Guangzhou
2026-01-08
Recruiting
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT07222566Advanced Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Carcinoma, Non-Small-Cell Lung (NSCLC)
DrugsPF-08634404·Pembrolizumab
Pfizer
Phase 3
1,410
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Huizhou, Jiangmen, Nanning
2026-01-06
Not yet open
Sun Yat-sen University
Phase 2
50
Guangzhou
2026-01-05
Recruiting
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
30
Guangzhou, Zhengzhou, Wuhan, Xiangyang, Changsha, Nanjing, Nantong, Nanchang
2026-01-05
Recruiting
Sun Yat-sen University
Phase 2
80
Guangzhou
2026-01-05
Recruiting
Bristol-Myers Squibb
Phase 2/3
590
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Shenzhen, Nanning
2026-01-02
By invitation
Propranolol With Tislelizumab Plus GC in Neoadjuvant Bladder UC
NCT07353294Bladder Urothelial Carcinoma, Lymph Node Metastasis
DrugsPropranolol·Tislelizumab·Gemcitabine·Cisplatin
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 1
12
Guangzhou
2026-01-01
Active, closed
PT-MSCs Exosome Injection in the Treatment of Chronic-to-acute Liver Failure
NCT07409259Acute-on-Chronic Liver Failure (ACLF)
Third Affiliated Hospital, Sun Yat-Sen University
Early Phase 1
20
Guangzhou
2026-01-01
Not yet open
Stereotactic Aspiration of Brain Stem Hematoma
NCT07300501Brain Stem Hematoma
First Affiliated Hospital of Zhejiang University
Not applicable
300
Hangzhou, Changsha, Guangzhou, Jinan, Shanghai, Shenzhen, Taizhou, Wenzhou
2026-01-01
Recruiting
Sixth Affiliated Hospital, Sun Yat-sen University
Phase 2
76
Guangzhou
2026-01-01
Recruiting
Magnetic Tracking and ECG-Guided Tip Confirmation System for PICCs
NCT07369427Peripherally Inserted Central Catheters
Sun Yat-sen University
Observational
176
Guangzhou
2026-01-01
Not yet open
Prenatal Exercise Including Perineal Massage and Maternal-Neonatal Outcomes
NCT07314502Postpartum Urinary Incontinence, Postpartum Depression (PPD), Neonatal Complications, Gestational Diabetes
South China Normal University
Not applicable
2,000
Guangzhou
2026-01-01
Not yet open
Beijing Children's Hospital
Not applicable
2,650
Beijing, Chongqing, Guangzhou, Baoding, Zhengzhou, Wuxi, Changchun, Xi'an
2026-01-01
Not yet open
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Observational
150
Guangzhou
2026-01-01
Not yet open
First Affiliated Hospital, Sun Yat-Sen University
Observational
5,400
Guangzhou
2026-01-01
Active, closed
DIEP-MDS for Risk Stratification of Flap Vascular Compromise and Failure in Breast Reconstruction
NCT07761390Breast Neoplasms, Breast Reconstruction, Postoperative Complications
Zhuliling
Observational
1,500
Xiamen, Dongguan, Guangzhou, Huizhou, Meizhou, Shantou, Shanwei, Shaoguan
2026-01-01
Not yet open
Sun Yat-sen University
Phase 2
30
Guangzhou
2026-01-01
Recruiting
Large Language Models Assist in Tumor MDT
NCT07504367Lung Cancer, Breast Cancer, Colorectal Cancer, Stomach Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Not applicable
60
Guangzhou
2026-01-01
Recruiting
Guangzhou Center for Disease Control and Prevention
Not applicable
320
Guangzhou
2026-01-01
Recruiting
A Study of Chiglitazar in Patients With Metabolic Dysfunction-associated Steatohepatitis and Type 2 Diabetes Mellitus
NCT07303803MASH - Metabolic Dysfunction-Associated Steatohepatitis, T2DM (Type 2 Diabetes Mellitus)
DrugsChiglitazar·Vitamin E
Shanghai Jiao Tong University School of Medicine
Phase 2
300
Beijing, Chongqing, Fuzhou, Guangzhou, Wuhan, Shiyan, Changsha, Changchun
2026-01-01
Recruiting
Sintilimab Plus Chemotherapy as Neoadjuvant and Adjuvant Treatment for Locally Advanced Oral Squamous Cell Carcinoma
NCT07371611Locally Advanced Oral Squamous Cell Carcinoma, Oral Squamous Cell Carcinoma (OSCC)
DrugsSintilimab·Nab-paclitaxel·Cisplatin·Carboplatin
Qunxing Li,MD
Phase 3
104
Guangzhou
2026-01-01
Recruiting
First Affiliated Hospital, Sun Yat-Sen University
Not applicable
1,000
Guangzhou
2026-01-01
Recruiting
Cardiovascular Outcomes and Risk Evaluation Among Recipients of Hematopoietic Stem Cell Transplantation
NCT07349498Hematopoietic Stem Cell Transplantation, Transplant Complication, Cardiovascular Events
Peking University People's Hospital
Observational
10,000
Beijing, Chongqing, Guangzhou, Shenzhen, Harbin, Zhengzhou, Wuhan, Xi'an
2026-01-01
Recruiting
Sun Yat-sen University
Phase 2
56
Guangzhou
2026-01-01
Active, closed
Sixth Affiliated Hospital, Sun Yat-sen University
Not applicable
60
Guangzhou
2026-01-01
Not yet open
Nanfang Hospital, Southern Medical University
Phase 4
113
Guangzhou
2026-01-01
Not yet open
Guangzhou University of Traditional Chinese Medicine
Observational
3,000
Beijing, Guangzhou, Weihui, Shanghai, Chengdu
2026-01
Not yet open
TransThera Sciences (Nanjing), Inc.
Phase 3
138
Hefei, Fuzhou, Guangzhou, Zhengzhou, Wuhan, Changsha, Nanjing, Nanchang
2026-01
Not yet open
Nanfang Hospital, Southern Medical University
Not applicable
536
Guangzhou
2026-01
Recruiting
Cytori Therapeutics
Not applicable
48
Guangzhou, Shanghai
2025-12-31
Recruiting
Bristol-Myers Squibb
Phase 2/3
990
Hefei, Chongqing, Fuzhou, Fuzhou Fujian, Guangzhou, Shenzhen, Nanning, Tianjin
2025-12-31
Recruiting
Neoadjuvant SBRT Followed by Sintilimab Plus Chemotherapy for N3-Positive NSCLC
NCT07309952Locally Advanced Non-Small Cell Lung Cancer, Stage IIIb Non-small Cell Lung Cancer, Stage IIIC Non-Small Cell Lung Cancer
DrugsSintilimab·Pemetrexed·Paclitaxel·Carboplatin
Yang Hong
Phase 2
28
Guangzhou
2025-12-31
Recruiting
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2
416
Guangzhou
2025-12-31
Recruiting
Active Surveillance and Safety/Efficacy Evaluation of Innovative Devices for Structural Heart Disease Intervention
NCT07848152Transcatheter Mitral Valve Edge-to-Edge Repair System, Biodegradable Patent Foramen Ovale Closure Device
Shanghai Jiao Tong University School of Medicine
Observational
2,200
Lanzhou, Guangzhou, Zhengzhou, Wuhan, Shenyang, Jinan, Chengdu, Kunming
2025-12-30
Not yet open
Nanfang Hospital, Southern Medical University
Observational
32
Guangzhou
2025-12-30
Recruiting
The First Affiliated Hospital of Guangdong Pharmaceutical University
Not applicable
40
Guangzhou
2025-12-30
Not yet open
Sixth Affiliated Hospital, Sun Yat-sen University
Not applicable
590
Guangzhou
2025-12-30
Recruiting
Sun Yat-sen University
Phase 2
80
Guangzhou, Zhengzhou
2025-12-30
Recruiting
Xian-Janssen Pharmaceutical Ltd.
Phase 4
78
Guangzhou, Hangzhou, Hefei, Shanghai
2025-12-30
Recruiting
Zhongshan Ophthalmic Center, Sun Yat-sen University
Early Phase 1
9
Beijing, Guangzhou
2025-12-29
Not yet open
PD-1 + FOLFOXIRI vs CAPOX as Total Neoadjuvant Therapy for pMMR Low Rectal Cancer
NCT07277842Locally Advanced Low Rectal Adenocarcinoma, pMMR (Microsatellite Stable Rectal Cancer)
DrugSerplulimab
Sun Yat-sen University
Phase 3
382
Guangzhou
2025-12-29
Recruiting
Alpha Biopharma (Jiangsu) Co., Ltd.
Observational
800
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Foshan, Guangzhou, Meizhou
2025-12-29
Recruiting
AstraZeneca
Phase 3
1,100
Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou
2025-12-29
Recruiting
Study on the Mechanism of ADC Drug Evaluation Based on Immune Co-culture of Lung Cancer Organoids
NCT07610616HER2 Positive OR TROP2 Positive Non-Small Cell Lung Cancer
Guangzhou Institute of Respiratory Disease
Observational
10
Guangzhou
2025-12-28
Recruiting
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
Phase 1/2
70
Beijing, Chongqing, Fuzhou, Guangzhou, Shenzhen, Guiyang, Baoding, Harbin
2025-12-26
Recruiting
QL1706 in Combination With Bevacizumab and RALOX HAIC for Hepatocellular Carcinoma With Vp3/4 PVTT
NCT07327788Hepatecellular Carcinoma, RALOX-HAIC（Hepatic Arterial Infusion Chemotherapy With Raltitrexed and Oxaliplatin, Bevacizumab, Type VP3/4 Portal Vein Tumor Thrombosis
DrugsIparomlimab and Tuvonralimab·Lenvatinib·Bevacizumab
Nanfang Hospital, Southern Medical University
Phase 2
38
Guangzhou
2025-12-25
Recruiting
Shanghai Junshi Bioscience Co., Ltd.
Phase 3
560
Hefei, Beijing, Fuzhou, Lanzhou, Wuwei, Guangzhou, Meizhou, Shantou
2025-12-24
Recruiting
Shenzhen Majory Biotechnology Co., Ltd.
Phase 1/2
45
Beijing, Chongqing, Fuzhou, Guangzhou, Shenzhen, Shijiazhuang, Harbin, Zhengzhou
2025-12-24
Not yet open
Garsorasib In KRAS G12C Mutant Locally Advanced and Metastatic NSCLC
NCT07294261Local Advanced or Metastatic NSCLC
Sun Yat-sen University
Phase 2
69
Guangzhou
2025-12-23
Recruiting
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 1
107
Guangzhou
2025-12-23
Recruiting
Second Affiliated Hospital of Guangzhou Medical University
Early Phase 1
8
Guangzhou
2025-12-22
Recruiting
Hansoh BioMedical R&D Company
Phase 1/2
502
Guangzhou
2025-12-22
Not yet open
Sun Yat-sen University
Phase 2
37
Guangzhou
2025-12-20
Active, closed
The First Affiliated Hospital of Guangzhou Medical University
Not applicable
30
Guangzhou
2025-12-19
Recruiting
Janssen Research & Development, LLC
Phase 3
800
Beijing, Chengdu, Chongqing, Guangzhou, Hangzhou, Nanjing, Shanghai, Tianjin
2025-12-19
Not yet open
Sun Yat-sen University
Observational
120
Guangzhou
2025-12-18
Recruiting
NucMito Pharmaceuticals Co. Ltd.
Phase 1
30
Xiamen, Guangzhou, Zhengzhou
2025-12-18
Recruiting
Shanghai EpimAb Biotherapeutics Co., Ltd.
Phase 2
54
Beijing, Guangzhou
2025-12-18
Recruiting
ArriVent BioPharma, Inc.
Phase 3
480
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Foshan, Guangzhou, Shantou
2025-12-17
Recruiting
Tian'an Jiang
Not applicable
85
Guangzhou, Hangzhou
2025-12-17
Recruiting
Prevention and Treatment of Radiation-Induced Oral Mucositis in NPC With Houyanqing Oral Liquid
NCT07311772Nasopharyngeal Cancinoma (NPC), Radiation-induced Oral Mucositis
Sun Yat-sen University
Phase 3
386
Beijing, Fuzhou, Guangzhou, Shantou, Zhuhai, Nanning, Wuzhou, Changsha
2025-12-16
Recruiting
Suzhou BlueHorse Therapeutics Co., Ltd.
Phase 2
92
Beijing, Fuzhou, Guangzhou, Nanning, Zhengzhou, Wuhan, Nanjing, Changchun
2025-12-16
Recruiting
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
Phase 1
42
Beijing, Guangzhou, Zhengzhou, Changsha, Nanjing, Nanchang, Dalian, Jinan
2025-12-16
Recruiting
Hutchmed
Phase 1/2
147
Beijing, Changsha, Guangzhou, Hefei, Shanghai, Shenyang, Zhengzhou
2025-12-16
Recruiting
Nanjing Leads Biolabs Co.,Ltd
Phase 1
117
Bengbu, Beijing, Guangzhou, Changsha, Nanjing, Pingxiang, Shanghai, Taiyuan
2025-12-16
Recruiting
AstraZeneca
Phase 2
320
Beijing, Changchun, Changsha, Guangzhou, Jiujiang, Kunming, Linyi, Nanchong
2025-12-15
Not yet open
Chunyan Ma
Observational
1,740
Guangzhou, Nanning, Harbin, Jiamusi, Zhengzhou, Nanjing, Nanchang, Changchun
2025-12-15
Recruiting
Eli Lilly and Company
Phase 3
1,035
Beijing, Chengdu, Chongqing, Guangzhou, Hefei, Jinan, Luoyang Shi, Nanchang
2025-12-15
Recruiting
Guangdong Association of Clinical Trials
Phase 2
120
Guangzhou, Meizhou, Shantou, Shenzhen
2025-12-15
Recruiting
Superior HypogastrIc plExus bLock During Laparoscopic Colorectal Cancer Surgery
NCT07579780Colorectal Cancer (Diagnosis), Laparoscopic Surgery, Superior Hypogastric Plexus Block
Sixth Affiliated Hospital, Sun Yat-sen University
Not applicable
170
Guangzhou
2025-12-15
By invitation
Guangdong Hengqin Novagains Biopharmaceutical Co., Ltd.
Phase 1
69
Guangzhou
2025-12-15
Not yet open
Tianjin Medical University Cancer Institute and Hospital
Phase 2
188
Guangzhou, Shijiazhuang, Luoyang, Nanyang, Chengdu, Tianjin, Jiaxing
2025-12-15
Recruiting
Xijing Hospital of Digestive Diseases
Phase 3
132
Guangzhou, Xi'an
2025-12-15
Recruiting
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
NCT07218380Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, Neoplasm Metastasis
DrugsVepugratinib·Pembrolizumab
Eli Lilly and Company
Phase 3
450
Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin
2025-12-12
Recruiting
Pfizer
Phase 3
800
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Meizhou, Nanning
2025-12-11
Recruiting
JHM BioPharma (Tonghua) Co. , Ltd.
Phase 3
207
Bengbu, Hefei, Beijing, Chongqing, Guangzhou, Nanning, Cangzhou, Shijiazhuang
2025-12-11
Recruiting
A Study of the Efficacy and Safety of Extracorporeal Carbon Dioxide Removal Using PrismaLung+
NCT07326215Acute Respiratory Distress Syndrome, Acute Kidney Injury
Vantive Health LLC
Not applicable
99
Beijing, Guangzhou, Shenzhen, Harbin, Nanjing, Nanchang, Shanghai, Chengdu
2025-12-11
Not yet open
Sixth Affiliated Hospital, Sun Yat-sen University
Phase 2
40
Guangzhou
2025-12-11
Recruiting
BeOne Medicines
Phase 1
86
Beijing, Chongqing, Xiamen, Guangzhou, Harbin, Changsha, Nanjing, Shanghai
2025-12-11
Recruiting
BeOne Medicines
Phase 1
105
Beijing, Guangzhou, Harbin, Wuhan, Nanjing, Jinan, Weifang
2025-12-11
Recruiting
Xian-Janssen Pharmaceutical Ltd.
Observational
200
Beijing, Changzhou, Guangzhou, Hangzhou, Nanjing, Shenzhen, Shijiazhuang, Tianjin
2025-12-11
Recruiting
Changhai Hospital
Not applicable
376
Chongqing, Guangzhou, Shenzhen, Kaifeng, Zhengzhou, Changsha, Suzhou, Nanchang
2025-12-10
Recruiting
InSilico Medicine Hong Kong Limited
Phase 2
80
Beijing, Chongqing, Guangzhou, Huizhou, Nanning, Shijiazhuang, Luoyang, Xinxiang
2025-12-10
Recruiting
The Effects of Vonoprazan Fumarate on DGF Incidence in DD Kidney Transplant Recipients
NCT07275632Delayed Graft Function, Kidney Transplantation
First Affiliated Hospital of Chongqing Medical University
Phase 1/2
47
Chongqing, Guangzhou
2025-12-10
By invitation
Optimal Interval for Periodic Alveolar Recruitment Maneuvers Achieving 90% Lung Re-expansion During Intraoperative Ventilation
NCT07239557Major Abdominal Surgery, Atelectasis, Lung-protective Ventilation, Lung Ultrasound Score
Sixth Affiliated Hospital, Sun Yat-sen University
Not applicable
52
Guangzhou
2025-12-10
Recruiting
Wecare Probiotics Co., Ltd.
Not applicable
375
Guangzhou
2025-12-10
Recruiting
AbbVie
Phase 2/3
490
Guangzhou, Nanchang, Shanghai, Ürümqi
2025-12-10
Recruiting
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 1
42
Chongqing, Guangzhou, Chengde, Tangshan, Nanjing, Suzhou, Nanchang, Xi'an
2025-12-09
Recruiting
Pfizer
Phase 2/3
550
Guangzhou, Shanghai
2025-12-09
Recruiting
Tongji Hospital
Observational
40
Beijing, Guangzhou, Wuhan, Shanghai, Hangzhou
2025-12-09
Recruiting
Eli Lilly and Company
Phase 2
60
Beijing, Chengdu, Guangzhou, Luoyang, Shanghai, Xuzhou
2025-12-08
Recruiting
Phase II Clinical Study of Probiotic LR607 in Patients With Non-Small Cell Lung Cancer
NCT07534033NSCLC Diagnosed by Histology or Cytology, A Multidisciplinary Team Assessment Determined That the Patient Was a Suitable Candidate for Radical Surgical Resection, Overall Lung Function is Adequate for the Planned Lung Resection, AJCC is Classified as IIA-IIIB
Zhujiang Hospital
Phase 2
46
Guangzhou
2025-12-06
Recruiting
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Not applicable
258
Guangzhou
2025-12-05
Recruiting
AstraZeneca
Phase 3
1,100
Beijing, Changchun, Changde, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou
2025-12-04
Recruiting
Association Between Clinical Classification and Prognosis in Chronic Radiation Enteropathy
NCT07378631Radiotherapy, Radiation Proctitis, Radiation Enteritis
Sixth Affiliated Hospital, Sun Yat-sen University
Observational
150
Guangzhou
2025-12-04
Recruiting
Merck Sharp & Dohme LLC
Phase 2
150
Beijing, Xiamen, Guangzhou, Harbin, Wuhan, Changsha, Nanjing, Nanchang
2025-12-04
Recruiting
Takeda
Phase 3
110
Beijing, Guangzhou, Changsha, Hangzhou, Shanghai
2025-12-04
Recruiting
BioNTech SE
Phase 2
105
Beijing, Changchun, Chengdu, Dalian, Guangzhou, Hangzhou, Jinan, Kunming
2025-12-04
Recruiting
Janssen Research & Development, LLC
Phase 3
600
Beijing, Bengbu, Changsha, Chengdu, Chongqing, Dongguan, Guangzhou, Hangzhou
2025-12-03
Recruiting
Daiichi Sankyo
Phase 1
60
Guangzhou, Shanghai, Wenzhou
2025-12-03
Recruiting
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 1/2
200
Guangzhou
2025-12-03
Recruiting
Bristol-Myers Squibb
Phase 3
366
Beijing, Guangzhou, Shenzhen, Handan, Zhengzhou, Changsha, Jinan, Shanghai
2025-12-03
Recruiting
GlaxoSmithKline
Phase 3
450
Shijiazhuang, Shanghai, Beijing, Chengdu, Chongqing, Guangzhou, Hangzhou, Jinan
2025-12-03
Recruiting
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
Phase 3
566
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou, Guangzhou, Shenzhen
2025-12-02
Recruiting
Bristol-Myers Squibb
Phase 3
650
Beijing, Haidian District, Guangzhou, Shenzhen, Changsha, Nanjing, Tianjin, Hangzhou
2025-12-02
Recruiting
Nanjing Leads Biolabs Co.,Ltd
Phase 1/2
180
Beijing, Fuzhou, Guangzhou, Harbin, Anyang, Zhengzhou, Xuzhou, Shenyang
2025-12-02
Not yet open
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 3
852
Guangzhou
2025-12-01
Active, closed
Guangdong Hengrui Pharmaceutical Co., Ltd
Phase 2
21
Guangzhou
2025-12-01
Recruiting
Dizal (Jiangsu) Pharmaceutical Co., Ltd.
Phase 3
360
Beijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin
2025-12-01
Recruiting
Sixth Affiliated Hospital, Sun Yat-sen University
Phase 4
200
Guangzhou
2025-12-01
By invitation
Jingchu Hu
Not applicable
140
Guangzhou
2025-12-01
Recruiting
Sixth Affiliated Hospital, Sun Yat-sen University
Observational
909
Guangzhou
2025-12-01
Not yet open
Zhujiang Hospital
Phase 1
9
Guangzhou
2025-12-01
Recruiting
Eli Lilly and Company
Phase 3
7,140
Beijing, Changchun, Changde, Changzhou, Chengdu, Chongqing, Dalian, Guangzhou
2025-12-01
Recruiting
DEB-TACE vs cTACE in HCC After TIPS
NCT07322848Hepatocellular Carcinoma (HCC), TACE, TIPS, DEB-TACE
First Affiliated Hospital, Sun Yat-Sen University
Phase 3
206
Guangzhou
2025-12-01
Not yet open
Sun Yat-sen University
Phase 2
236
Guangzhou
2025-12-01
Recruiting
Nanfang Hospital, Southern Medical University
Observational
90
Guangzhou
2025-12-01
Recruiting
Wen-zhao ZHONG
Not applicable
300
Guangzhou
2025-12-01
Recruiting
Central China Fuwai Hospital of Zhengzhou University
Not applicable
738
Beijing, Chongqing, Guangzhou, Zhengzhou, Wuhan, Changsha, Nanjing, Qingdao
2025-12-01
Recruiting
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Observational
600
Guangdong, Guangzhou
2025-12-01
Recruiting
Human Sinonasal Mucosa Heterogeneity Study
NCT07692243Human Sinonasal Mucosal Spatial Atlas
First Affiliated Hospital, Sun Yat-Sen University
Observational
100
Guangzhou
2025-12-01
Active, closed
UCB Biopharma SRL
Phase 4
40
Beijing, Changchun, Changsha, Fuzhou, Guangzhou, Jinan, Shanghai, Shenzhen
2025-12-01
Not yet open
Shanghai Changzheng Hospital
Observational
1,100
Beijing, Guangzhou, Nanjing, Suzhou, Shanghai, Chengdu, Ningbo
2025-12
Recruiting
Zai Lab (Shanghai) Co., Ltd.
Phase 3
480
Hefei, Fuzhou, Xiamen, Guangzhou, Naning, Heilongjiang, Shijiazhuang, Zhengzhou
2025-11-30
Recruiting
Dong sheng Zhang
Phase 1/2
48
Guangzhou
2025-11-28
Recruiting
A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer
NCT07169851Nausea, Vomiting, Drug-Related Side Effects and Adverse Reactions, Neoplasms
Eli Lilly and Company
Phase 2
204
Changde, Guangzhou, Hangzhou, Jiangmen, Luoyang
2025-11-28
Recruiting
Guangzhou Lupeng Pharmaceutical Company LTD.
Phase 2
150
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Meizhou, Nanning, Shijiazhuang
2025-11-27
Recruiting
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 2
135
Wuhu, Beijing, Chongqing, Fuzhou, Guangzhou, Shijiazhuang, Jingzhou, Changsha
2025-11-27
Recruiting
A Study of MHB042C in Patients With Advanced Solid Tumors
NCT07192107Advanced Malignant Solid Tumor
Minghui Pharmaceutical (Hangzhou) Ltd
Phase 1/2
200
Guangzhou
2025-11-27
Active, closed
Alexion Pharmaceuticals, Inc.
Phase 2
78
Beijing, Guangzhou, Hangzhou, Nanchang
2025-11-26
Recruiting
A Study Comparing TAK-928 With Docetaxel in Adults With Non-Small Cell Lung Cancer
NCT07217301IO Resistant Squamous and Nonsquamous NSCLC
Takeda
Phase 3
1,200
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Shijiazhuang, Harbin, Xinxiang
2025-11-26
Recruiting
Sixth Affiliated Hospital, Sun Yat-sen University
Phase 2
38
Guangzhou
2025-11-26
Recruiting
Sun Yat-sen University
Phase 1
12
Guangzhou
2025-11-25
Not yet open
Efficacy and Safety of Stapokibart in Non-Allergic Rhinitis With Eosinophilia Syndrome
NCT07240376Non-Allergic Rhinitis With Eosinophilia Syndrome
DrugStapokibart
Huazhong University of Science and Technology
Not applicable
90
Guangzhou, Wuhan, Xiangyang, Nanchang, Chengdu, Beijing, Shanghai
2025-11-25
Recruiting
Nanfang Hospital, Southern Medical University
Observational
1,680
Guangzhou
2025-11-24
Not yet open
Sun Yat-sen University
Observational
229
Guangzhou
2025-11-24
Recruiting
Hoffmann-La Roche
Phase 3
900
Beijing, Changchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Nanjing
2025-11-24
Recruiting
A Platform Study in Non-Small Cell Lung Cancer (NSCLC)
NCT06996782Advanced or Metastatic Non-small Cell Lung Cancer
DrugsRamucirumab·Rilvegostomig·Nab-paclitaxel·Pemetrexed
AstraZeneca
Phase 1/2
152
Chengdu, Chongqing, Deyang, Fuzhou, Guangzhou, Jinan, Shanghai, Shenyang
2025-11-24
Recruiting
Shanghai Hengrui Pharmaceutical Co., Ltd.
Phase 2
300
Guangzhou
2025-11-24
Recruiting
Iparomlimab and Tuvonralimab (QL1706) Combination With Lenvatinib as Neoadjuvant Therapy for ccRCC
NCT07389629Iparomlimab and Tuvonralimab, Clear Cell Renal Cell Carcinoma, Neoadjuvant Therapy
DrugLenvatinib
Sun Yat-sen University
Phase 2
25
Guangzhou
2025-11-21
Recruiting
GlaxoSmithKline
Phase 3
75
Leshan, Beijing, Changsha, Chengdu, Chongqing, Dongguan, Ganzhou, Guangzhou
2025-11-21
Recruiting
TJ Biopharma Co., Ltd.
Phase 3
30
Beijing, Guangzhou, Nanning, Shijiazhuang, Zhengzhou, Wuhan, Nanchang, Shenyang
2025-11-21
Recruiting
Pfizer
Phase 2
165
Fuzhou, Guangzhou, Shanghai, Beijing
2025-11-20
Recruiting
Ming-Yuan Chen
Phase 3
346
Hefei, Fuzhou, Guangzhou, Shantou, Zhongshan, Zhuhai, Nanning, Wuzhou
2025-11-20
Recruiting
Sun Yat-sen University
Phase 2
96
Guangzhou, Wuhan, Nanchang, Kunming
2025-11-20
Active, closed
MedtronicNeuro
Not applicable
61
Beijing, Guangzhou, Shanghai, Chengdu
2025-11-19
Not yet open
Chengdu Syncor Pharmaceutical Co., Ltd.
Phase 1/2
195
Guangzhou
2025-11-19
Active, closed
Bayer
Phase 2
60
Beijing, Guangzhou, Wuhan, Hangzhou
2025-11-19
Recruiting
Ming-Yuan Chen
Phase 3
456
Guangzhou, Shantou, Zhongshan, Nanning, Wuzhou, Wuhan, Changsha, Guangdong
2025-11-18
Recruiting
Summit Therapeutics
Phase 3
900
Beijing, Fuzhou, Guangzhou, Foshan, Shenzhen, Zhuhai, Haikou, Shijiazhuang
2025-11-18
Active, closed
Sun Yat-sen University
Phase 3
700
Dongguan, Guangzhou, Shantou, Shenzhen, Zhanjiang
2025-11-17
Recruiting
AstraZeneca
Observational
200
Beijing, Cangzhou, Dongguan, Fuzhou, Guangzhou, Huzhou, Jinan, Nanjing
2025-11-17
Recruiting
Nanfang Hospital, Southern Medical University
Observational
1,500
Guangzhou
2025-11-15
Recruiting
Yiyuancong for the Treatment of Sudden Sensorineural Hearing Loss
NCT07505667Sudden Hearing Loss, Sensorineural Hearing Loss
Guangdong Provincial People's Hospital
Not applicable
128
Guangzhou, Shenzhen, Zhongshan, Liuzhou, Ganzhou
2025-11-15
Recruiting
Affiliated Cancer Hospital & Institute of Guangzhou Medical University
Phase 2
40
Guangzhou
2025-11-15
Recruiting
UCB Biopharma SRL
Phase 3
320
Beijing, Chengdu, Chongqing, Guangzhou, Hangzhou, Jinan, Shanghai, Shenzhen
2025-11-14
Recruiting
Degron Therapeutics Co.
Phase 1
100
Beijing, Guangzhou
2025-11-13
Recruiting
Sun Yat-sen University
Phase 3
802
Guangzhou
2025-11-13
Recruiting
Sun Yat-sen University
Phase 2
35
Guangzhou
2025-11-13
Recruiting
Hansoh BioMedical R&D Company
Phase 1
60
Guangzhou
2025-11-13
Recruiting
AstraZeneca
Phase 1/2
83
Guangzhou, Tianjin
2025-11-12
Recruiting
Jiangsu HengRui Medicine Co., Ltd.
Phase 2
200
Guangzhou
2025-11-12
Recruiting
Novartis Pharmaceuticals
Phase 3
1,275
Guangzhou, Zunyi, Zhengzhou, Wuhan, Hohhot, Suzhou, Changchun, Shenyang
2025-11-11
Recruiting
Sixth Affiliated Hospital, Sun Yat-sen University
Phase 3
60
Guangzhou
2025-11-11
Recruiting
AstraZeneca
Phase 3
420
Beijing, Changchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Haikou
2025-11-11
Recruiting
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1
33
Guangzhou
2025-11-11
Recruiting
Staidson (Beijing) Biopharmaceuticals Co., Ltd
Phase 3
300
Beijing, Chongqing, Xiamen, Lanzhou, Guangzhou, Meizhou, Shaoguan, Shenzhen
2025-11-10
Recruiting
Joincare Pharmaceutical Group Industry Co., Ltd
Phase 3
177
Guangzhou
2025-11-07
Recruiting
Guangdong Hengrui Pharmaceutical Co., Ltd
Phase 2
75
Guangzhou
2025-11-07
Active, closed
South China Normal University
Not applicable
90
Guangzhou
2025-11-06
Recruiting
A Phase IIa, Randomized, Double-Blind, Placebo-Controlled Trial of JKN2403 in COPD
NCT07351734COPD (Chronic Obstructive Pulmonary Disease)
Joincare Pharmaceutical Group Industry Co., Ltd
Phase 2
120
Guangzhou
2025-11-06
Recruiting
Sanofi
Phase 2
208
Chengdu, Guangzhou, Shanghai, Ürümqi
2025-11-06
Recruiting
SPH Qingdao Growful Pharmacetical Co.,Ltd
Phase 4
2,708
Haozhou, Beijing, Chongqing, Lanzhou, Guangzhou, Shantou, Zhuhai, Guilin
2025-11-06
Recruiting
Adaptive Adjuvant Sintilimab Therapy Guided by MRD (ADAPT Lung)
NCT07120698NSCLC (Non-small Cell Lung Cancer), MRD, II-IIIB Stages, Adjuvant Immunotherapy
DrugSintilimab
Guangdong Association of Clinical Trials
Phase 2
115
Guangzhou, Chengdu
2025-11-05
Recruiting
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1/2
202
Chongqing, Fuzhou, Xiamen, Zhangzhou, Dongguan, Guangzhou, Jiangmen, Shaoguan
2025-11-05
Recruiting
Sun Yat-sen University
Phase 2
30
Guangzhou
2025-11-05
Active, closed
Suzhou HepaThera Biotech Co., Ltd.
Phase 2
60
Beijing, Fuzhou, Guangzhou, Qingyuan, Nanning, Zhengzhou, Nanjing, Zhenjiang
2025-11-05
Recruiting
Shanghai Synvida Biotechnology Co.,Ltd.
Phase 2
48
Chengdu, Guangzhou, Hangzhou, Nanchang, Nanjing, Neimeng, Shanghai, Tianjin
2025-11-04
Recruiting
Guangdong Association of Clinical Trials
Phase 2
48
Guangzhou, Beijing, Foshan, Nanchang, Nanning, Shijiazhuang
2025-11-03
By invitation
Sun Yat-sen University
Phase 2
60
Guangzhou
2025-11-01
By invitation
Nanfang Hospital, Southern Medical University
Not applicable
1,000
Guangzhou, Zhengzhou
2025-11-01
Recruiting
Xiang Gao
Observational
1,400
Guangzhou
2025-11-01
Not yet open
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
Phase 3
228
Beijing, Chongqing, Lanzhou, Guangzhou, Guiyang, Haikou, Harbin, Zhengzhou
2025-11
Recruiting
Staidson (Beijing) Biopharmaceuticals Co., Ltd
Phase 3
406
Beijing, Xiamen, Guangzhou, Zunyi, Luoyang, Zhengzhou, Wuhan, Xiangtan
2025-10-31
Recruiting
Eli Lilly and Company
Phase 3
1,205
Beijing, Chengdu, Guangzhou, Harbin, Luoyang Shi, Nanjing, Shanghai, Tianjin
2025-10-31
Recruiting
Camrelizumab and Apatinib With or Without FOLFOX Chemotherapy for Advanced HCC
NCT07267806Hepato Cellular Carcinoma (HCC), Chemotherapy Effect
DrugCamrelizumab and apatinib
Linhui Peng
Phase 3
326
Guangzhou
2025-10-31
Recruiting
AstraZeneca
Phase 3
400
Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou
2025-10-31
Recruiting
Evaluation of the Safety and Effectiveness of CHORDS® Cerebral Protection System During TAVR: DUET Trial
NCT07648693Transcatheter Aortic Valve Replacement (TAVR), Cerebral Vascular Accident (CVA)/Stroke
Resonova (Shanghai) Medtech Limited
Not applicable
240
Bengbu, Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Nanchang, Qingdao
2025-10-31
Recruiting
AstraZeneca
Phase 3
100
Beijing, Changsha, Guangzhou, Linyi, Shandong, Wuhan, Zhengzhou
2025-10-30
Active, closed
Sun Yat-sen University
Phase 2
30
Guangzhou
2025-10-30
Recruiting
Pfizer
Phase 2
200
Beijing, Guangzhou, Shijiazhuang, Shanghai, Tianjin, Hangzhou
2025-10-30
Active, closed
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 3
582
Guangzhou
2025-10-30
Recruiting
GlaxoSmithKline
Phase 2
363
Beijing, Chongqing, Dongguan, Guangzhou, Guilin, Hangzhou, Huizhou, Jiangmen
2025-10-30
Active, closed
GlaxoSmithKline
Phase 3
750
Beijing, Xiangtan, Nanjing, Chengdu, Chongqing, Guangzhou, Jiujiang, Kunming
2025-10-29
Recruiting
Gracell Biotechnologies (Shanghai) Co., Ltd.
Phase 1
12
Beijing, Changchun, Guangzhou, Hangzhou, Suzhou, Wenzhou, Wuhan
2025-10-29
Recruiting
A Study of YL201 and Ivonescimab (AK112) in Advanced Solid Tumors
NCT07208773Advanced Solid Tumors, Non Small Cell Lung Cancer, Small Cell Lung Cancer
DrugsTam-Peli·Ivonescimab
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1/2
260
Guangzhou
2025-10-29
Active, closed
Kylonova (Xiamen) Biopharma co., LTD.
Phase 2
204
Beijing, Baotou, Changde, Chongqing, Dali, Daqing, Guangzhou, Harbin
2025-10-29
Recruiting
O&D BioTech Group CO., Limited
Phase 1
18
Guangzhou
2025-10-28
Recruiting
QL1706 Plus Chemotherapy as Neoadjuvant Therapy for Locally Advanced Cervical Cancer: A Phase II Trial
NCT07286253Neoadjuvant Treatment for Locally Advanced Cervical Cancer
Affiliated Cancer Hospital & Institute of Guangzhou Medical University
Phase 2
50
Guangzhou
2025-10-28
Recruiting
HC Biopharma Inc.
Phase 1
328
Guangzhou
2025-10-27
Recruiting
A Phase 1/2 Study of PRO-203 in Healthy Volunteers and Participants With Systemic Sclerosis.
NCT07641634Healthy Volunteers, Systemic Sclerosis (SSc), Scleroderma, Systemic, Scleroderma
Prolium Bioscience, Inc
Phase 1/2
44
Beijing, Guangzhou, Henan, Nanchang, Nanjing, Pingxiang
2025-10-27
Recruiting
Stereotactic Thrombolysis With Tenecteplase for Supratentorial Intracerebral Hemorrhage
NCT07208097Intracerebral Haemorrhage, Minimally Invasive Treatment
Tongji Hospital
Not applicable
768
Anqing, Hefei, Suzhou, Guangzhou, Nanning, Bijie, Guiyang, Kaili
2025-10-25
Recruiting
Guangdong Association of Clinical Trials
Not applicable
40
Guangzhou
2025-10-25
Recruiting
Hoffmann-La Roche
Phase 3
600
Hefei, Nanchang, Hangzhou, Beijing, Bengbu, Changsha, Chengdu, Guangzhou
2025-10-24
Recruiting
Daiichi Sankyo
Phase 3
686
Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin
2025-10-24
Recruiting
JSKN022 in Subjects With Advanced Malignant Solid Tumors
NCT07292402Advanced Malignant Solid Tumors
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Phase 1
225
Guangzhou
2025-10-23
Active, closed
Bristol-Myers Squibb
Phase 2/3
470
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Harbin, Luoyang, Zhengzhou
2025-10-23
Recruiting
MAXVAX Biotechnology Limited Liability Company
Phase 3
25,000
Guangzhou, Shijiazhuang, Zhengzhou, Wuhan, Changsha, Xi'an, Jinan, Chengdu
2025-10-22
Recruiting
Eli Lilly and Company
Phase 3
1,630
Beijing, Changchun, Changde, Changsha, Chengdu, Guangzhou, Hangzhou, Jinan
2025-10-22
Recruiting
Nanfang Hospital, Southern Medical University
Not applicable
84
Guangzhou
2025-10-22
Recruiting
Genfleet Therapeutics (Shanghai) Inc.
Phase 1/2
126
Beijing, Guangzhou, Zhengzhou, Wuhan
2025-10-21
Recruiting
PD-L1 Inhibitor Rechallenge After Immunotherapy-Related Pneumonitis in Patients With Lung Cancer
NCT07775820Lung Cancer, Rechallenge, Checkpoint Inhibitor Pneumonitis
Nanfang Hospital, Southern Medical University
Observational
150
Guangzhou, Shenzhen, Nanchang, Wenzhou
2025-10-20
Recruiting
Risk Factors Affecting MSC Efficacy in ACLF Patients
NCT07198854Acute-On-Chronic Liver Failure
Sun Yat-sen University
Observational
446
Guangzhou
2025-10-20
Recruiting
Haplo-Cord HSCT for AML/MDS
NCT07588360MDS (Myelodysplastic Syndrome), AML (Acute Myeloid Leukemia)
Fujian Medical University Union Hospital
Not applicable
82
Fuzhou, Guangzhou, Chengdu, Beijing
2025-10-20
Recruiting
Affiliated Cancer Hospital & Institute of Guangzhou Medical University
Observational
110
Guangzhou
2025-10-20
Recruiting
Nanjing Leads Biolabs Co.,Ltd
Phase 2
140
Hefei, Fuzhou, Guangzhou, Nanning, Harbin, Zhengzhou, Xiangyang, Changsha
2025-10-20
Active, closed
BeiGene
Phase 4
16
Beijing, Guangzhou, Baoding, Yichang, Changsha, Hangzhou
2025-10-17
Recruiting
Eli Lilly and Company
Phase 3
1,100
Beijing, Changsha, Cheng Du Shi, Chengdu, Guangzhou, Hangzhou, Harbin, Hefei
2025-10-16
Not yet open
Sun Yat-sen University
Phase 2
128
Guangzhou
2025-10-15
Recruiting
Eli Lilly and Company
Phase 3
1,100
Beijing, Changsha, Cheng Du Shi, Chengdu, Guangzhou, Hangzhou, Harbin, Huzhou
2025-10-15
Recruiting
Bristol-Myers Squibb
Phase 1
32
Beijing, Fuzhou, Guangzhou, Shenzhen, Harbin, Xinxiang, Jinan, Tianjin
2025-10-15
Recruiting
Bristol-Myers Squibb
Phase 1/2
540
Guangzhou
2025-10-15
Recruiting
Eli Lilly and Company
Phase 3
4,500
Beijing, Changsha, Chengdu, Chongqing, Foshan, Fuzhou, Guangzhou, Guiyang
2025-10-15
Recruiting
Takeda
Phase 3
20
Beijing, Guangzhou, Jihan, Shanghai, Suzhou, Tianjin, Wuhan
2025-10-13
Recruiting
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2
56
Guangzhou
2025-10-13
Recruiting
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 3
530
Guangzhou
2025-10-09
Recruiting
Jiangsu HengRui Medicine Co., Ltd.
Phase 2
200
Guangzhou
2025-10-09
Recruiting
Bristol-Myers Squibb
Phase 3
424
Beijing, Guangzhou, Baoding, Shijiazhuang, Changsha, Nanjing, Xi'an, Chengdu
2025-10-08
Active, closed
Merck Sharp & Dohme LLC
Phase 2
185
Beijing, Xiamen, Guangzhou, Xinxiang, Pingxiang, Linfen, Ürümqi, Linhai
2025-10-08
Recruiting
Merck Sharp & Dohme LLC
Phase 3
675
Hefei, Beijing, Fujian, Fuzhou, Guangzhou, Nanning, Jiamusi, Zhengzhou
2025-10-08
Active, closed
Intervention to Reduce Sedentary Behavior During School Recess Among Adolescents
NCT07451535Sedentary Behaviour, Physical Activity, Adolescents, School-based Intervention
South China Normal University
Not applicable
1,000
Foshan, Guangzhou, Shenzhen, Zhuhai, Haikou, Jinzhong, Jinzhou
2025-10-08
Not yet open
Eye & ENT Hospital of Fudan University
Phase 4
360
Chongqing, Fuzhou, Guangzhou, Shenzhen, Harbin, Zhengzhou, Wuhan, Nanjing
2025-10-08
Recruiting
Janssen Research & Development, LLC
Phase 2/3
1,092
Beijing, Changsha, Changzhou, Chengdu, Chongqing, Foshan, Fuzhou, Guangzhou
2025-10-03
Recruiting
Novartis Pharmaceuticals
Phase 3
300
Beijing, Guangzhou, Luoyang, Xuzhou, Nanchang, Wenzhou, Fuzhou, Jining
2025-10-03
Recruiting
Pfizer
Phase 2/3
982
Hefei, Beijing, Fuzhou, Lanzhou, Guangzhou, Shenzhen, Baoding, Langfang
2025-10-03
Recruiting
Novo Nordisk A/S
Phase 3
1,280
Hefei, Beijing, Changchun, Fuzhou, Guangzhou, Guiyang, Shijiazhuang, Harbin
2025-10-02
Not yet open
Guangdong Association of Clinical Trials
Observational
600
Guangzhou
2025-10-01
Not yet open
Sun Yat-sen University
Phase 2
56
Guangzhou
2025-10-01
Recruiting
Zhujiang Hospital
Phase 1/2
46
Guangzhou
2025-10-01
Not yet open
The First Affiliated Hospital of Guangzhou Medical University
Phase 2
38
Guangzhou
2025-10-01
Not yet open
Sun Yat-sen University
Phase 2
150
Guangzhou
2025-10-01
Recruiting
Guangdong Provincial People's Hospital
Observational
20
Guangzhou
2025-10-01
Active, closed
Janssen Research & Development, LLC
Phase 3
896
Beijing, Changzhou, Cheng Du Shi, Chongqing, Foshan, Fuzhou, Guangzhou, Haikou
2025-10-01
Active, closed
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Observational
220
Guangzhou
2025-10-01
By invitation
Nanfang Hospital, Southern Medical University
Observational
2,000
Guangzhou, Zhongshan
2025-10-01
Recruiting
Sanofi
Phase 3
980
Xiamen, Guangzhou, Huizhou, Shenzhen, Wuhan, Changsha, Nanjing, Wuxi
2025-10-01
Recruiting
Xiong hao
Observational
360
Guangzhou
2025-10-01
Recruiting
Nanfang Hospital, Southern Medical University
Phase 3
154
Guangzhou
2025-10-01
Recruiting
Huashan Hospital
Phase 2/3
215
Beijing, Chengdu, Fuzhou, Guangzhou, Jinan, Nanchang, Nanjing, Shanghai
2025-10-01
By invitation
Nanfang Hospital, Southern Medical University
Observational
2,000
Guangzhou, Jinan
2025-10-01
Not yet open
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 3
210
Guangzhou, Wuhan, Changsha
2025-10
Not yet open
The IVO-LUNG Study
NCT07204548Non Small Cell Lung Cancer (Stage III)
DrugIvonescimab
Sun Yat-sen University
Phase 2
63
Guangzhou
2025-10
Not yet open
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Not applicable
912
Guangzhou
2025-10
Recruiting
Bristol-Myers Squibb
Phase 2/3
470
Beijing, Fuzhou, Xiamen, Guangzhou, Zhengzhou, Changsha, Nanjing, Nantong
2025-09-30
Not yet open
Beijing Friendship Hospital
Not applicable
256
Beijing, Changsha, Chengdu, Guangzhou, Jinan, Kunming, Nanjing, Shanghai
2025-09-30
Recruiting
AstraZeneca
Phase 1/2
52
Beijing, Chengdu, Guangzhou, Nanjing
2025-09-30
Recruiting
Eli Lilly and Company
Phase 3
1,000
Beijing, Chengdu, Chongqing, Guangzhou, Hangzhou, Hefei, Lanzhou, Nanjing
2025-09-30
Not yet open
YOLT-204 in Patients With Hemoglobinopathies
NCT07190001Hemoglobinopathies (Transfusion-dependent β-thalassemia and Sickle Cell Disease)
Guangzhou Women and Children's Medical Center
Early Phase 1
18
Guangzhou
2025-09-30
Not yet open
Changchun GeneScience Pharmaceutical Co., Ltd.
Phase 1
132
Guangzhou
2025-09-29
Recruiting
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 3
440
Guangzhou
2025-09-29
Recruiting
Genentech, Inc.
Phase 2
224
Fuzhou, Xiamen, Guangzhou, Huizhou, Zhengzhou, Wuhan, Changchun, Binzhou
2025-09-29
Recruiting
Pfizer
Phase 3
680
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Nanning, Harbin, Wuhan
2025-09-29
Recruiting
Hoffmann-La Roche
Observational
300
Langfang, Tianjin, Beijing, Changchun, Chengdu, Guangzhou, Harbin, Jinan
2025-09-29
Recruiting
Sun Yat-sen University
Phase 2
45
Guangzhou
2025-09-28
Recruiting
Guiding Value of Urinary Tumor DNA Testing in Repeat Transurethral Resection of Non-Muscle-Invasive Bladder Cancer
NCT07187635Bladder Cancer, Liquid Biopsy, Repeat Transurethral Resection of Bladder Tumor
Tianjin Medical University Second Hospital
Not applicable
350
Nanchang, Guangzhou, Xingtai, Kunming, Shanghai, Tianjin
2025-09-28
Recruiting
Pfizer
Phase 3
1,000
Wuhu, Beijing, Chongqing, Lanzhou, Guangzhou, Wuhan, Changsha, Huai'an
2025-09-28
Recruiting
Merck Sharp & Dohme LLC
Phase 2
315
Bengbu, Beijing, Guangzhou, Luoyang, Pingxiang, Changchun, Ürümqi, Kunming
2025-09-26
Recruiting
Daiichi Sankyo
Phase 2/3
630
Beijing, Chengdu, Guangzhou
2025-09-26
Not yet open
Beijing Tide Pharmaceutical Co., Ltd
Phase 2
40
Guangzhou
2025-09-26
Rows per page Showing 501–1000 of 3345
Previous 1 2 3 4 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 9 November 2026. https://priyalifescience.com/clinical-trials-china/city/guangzhou?page=2

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,187 studies in total at the last sync on 08 Nov 2026, 03:17 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 3,345 of those studies with a site in Guangzhou.

How many clinical trials are recruiting in Guangzhou?

1,977 of the 3,345 studies on this page are recruiting new participants as of the 08 Nov 2026, 03:17 UTC sync. A further 479 have not yet opened recruitment, 820 are active but closed to new participants, and 69 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.